Alnylam Pharmaceuticals (ALNY) Gains from Sales and Divestitures (2012 - 2015)
Alnylam Pharmaceuticals (ALNY) reported Gains from Sales and Divestitures of $159122.0 for Q4 2015, down 68.11% on a YoY basis from $499000.0 in Q4 2014, and down 68.11% quarter-over-quarter from $499000.0 in Q4 2014.
Alnylam Pharmaceuticals (ALNY) Gains from Sales and Divestitures (2012 - 2015) Analysis & Trends
Alnylam Pharmaceuticals has reported Gains from Sales and Divestitures for 4 years, with the latest figure at $159122.0 in Q4 2015.
- For the quarter ending Q4 2015, Gains from Sales and Divestitures fell 68.11% year-over-year to $159122.0; the trailing twelve-month figure through Dec 2015 stood at $159122.0 (down 68.11% YoY), and the FY2015 full-year result was $159122.0, down 68.11% from the prior year.
- Gains from Sales and Divestitures for Q4 2015 stood at $159122.0, down from $499000.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $499000.0 in Q4 2014, with the low at $105093.0 in Q4 2013.
- Historically, Gains from Sales and Divestitures has averaged $226238.8 across 4 years, with a median of $150431.0 in 2012.
- Annual changes were most pronounced in 2014 — Gains from Sales and Divestitures jumped 374.82% — and 2015, when it sank 68.11%.
- Alnylam Pharmaceuticals' Gains from Sales and Divestitures stood at $141740.0 in 2012, then decreased by 25.86% to $105093.0 in 2013, then surged by 374.82% to $499000.0 in 2014, then slumped by 68.11% to $159122.0 in 2015.
- The last three Gains from Sales and Divestitures figures came in at $159122.0 (Q4 2015), $499000.0 (Q4 2014), and $105093.0 (Q4 2013), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Alnylam Pharmaceuticals | 37.04 Bn | 34.03 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 159,122.00 |
| Dec 31, 2015 | 159,122.00 |
| Dec 31, 2014 | 499,000.00 |
| Dec 31, 2014 | 499,000.00 |
| Dec 31, 2013 | 105,093.00 |
| Dec 31, 2013 | 105,093.00 |
| Dec 31, 2012 | 141,740.00 |
| Dec 31, 2012 | 141,740.00 |